Recombinant 2019nCoV antigen-coronavirus Main Proteinase
Data Post Download
(Mpro, 3CLpro, His Tag)
Cat No.: GMP-V-2019nCoV-Mpro001
|Package||Catalog No.||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Expression platform||2019-nCoV(SARS-CoV-2, SARS2-coronavirus)|
Recombinant 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) Main Proteinase (Mpro, 3CLpro, His Tag)|
was expressed in E.coli-based prokaryotic cell expression system and the target gene encoding Ser1-Gln306
was expressed with 6 HIS tag at the N-terminus.
|Bioactivity validation||Enzyme activity validation in biochemical assay|
|Application||Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance. |
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
|predicted Molecular Mass||35kD|
|Formulation||Lyophilized from sterile PBS, PH 7.4|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|
2019nCoV (SARS-CoV-2) Mpro (3CLpro, 3C-Like protein, Nsp5)
About Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein)
COVID-19 pandemic is caused by 2019nCoV (SARS-CoV-2) infection. 2019nCoV contains 16 Non-structure protein (Nsp1-Nsp16) that may be drugable targets for antiviral compounds discovery against COVID-191.
2019nCoV (SARS-CoV-2) Mpro (Main Protease,Nsp5), also called 3C-Like Protein (3CLpro). The 2019nCoV (SARS-CoV-2) Mpro (3CLpro) mediates processing at 11 distinct cleavage sites, including its own autoproteolysis, and is essential for coronavirus replication. The coronavirus Mpro (3CLpro) exhibits a conserved three-domain structure and catalytic residues1,2.
High-throughput screening (HTS) assay development of coronavirus Mpro (3CLpro) for antiviral compounds
HTS Approach: Fluorescence resonance energy transfer (FRET) assay for time-dependent kinetic analysis
1.FRET Substrate: MCA-AVLQSGFR-Lys(Dnp)-Lys-NH22
2. Simple 2019nCoV (SARS-CoV-2) Mpro (3C-Likepro) activity assay develoement Protocol2: 2019nCoV (SARS-CoV-2) Mpro (3C-Likepro) activity assay develoement Protocol article
Gordon, D. E. et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. BioRxiv, doi:10.1101/2020.03.22.002386 (2020).
2. Jin, Z. et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature, doi:10.1038/s41586-020-2223-y (2020).